BioMotiv, Bristol-Myers alliance bears fruit with new company: Anteros Pharma
As a pharmaceutical accelerator that selects and incubates nascent technology from the halls of academia, BioMotiv is constantly in need of funding. Enter Bristol-Myers Squibb — who along with assimilating the arsenal of Celgene assets it acquired with the $74 billion acquisition of the big biotech company — is looking for fresh meat to bulk up its pipeline.
On Tuesday, BioMotiv and Bristol-Myers unveiled the first company borne out of their 2019 pact: Anteros Pharmaceuticals, which is focused on difficult-to-treat fibrotic and other inflammatory diseases, using technology in-licensed from Yale.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.